Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
checkpoint inhibitors
Biotech
ALX Oncology doubles down as lead asset fails 2 phase 2 trials
Evorpacept failed to meet the primary endpoints of two head and neck cancer trials, causing the company to scrap further attempts in the indication.
Darren Incorvaia
Apr 25, 2025 2:25pm
Sanofi passes $125M ILT2 asset back to Biond Biologics
Mar 3, 2025 11:00am
Pfizer to test Summit's white-hot bispecific with ADCs
Feb 24, 2025 9:17am
Incyte exits cancer pact, leaving Agenus weighing its options
Feb 11, 2025 7:55am
Pfizer's PD-1 prospect hits goal in phase 3 bladder cancer study
Jan 10, 2025 6:45am
BioNTech posts overall survival data on would-be Keytruda killer
Dec 10, 2024 9:00am
